Solomon Moshkevich Sells 80,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 80,000 shares of the stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $90.82, for a total value of $7,265,600.00. Following the completion of the transaction, the insider now directly owns 117,560 shares of the company’s stock, valued at $10,676,799.20. The sale was disclosed in a filing with the SEC, which is available through this link.

Natera Price Performance

NTRA opened at $87.28 on Friday. The stock has a fifty day moving average of $85.74 and a 200-day moving average of $65.57. The firm has a market capitalization of $10.54 billion, a P/E ratio of -23.03 and a beta of 1.37. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $98.82. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. The company had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. Equities analysts forecast that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Institutional Trading of Natera

A number of hedge funds have recently modified their holdings of the business. Crossmark Global Holdings Inc. raised its holdings in shares of Natera by 2.2% during the fourth quarter. Crossmark Global Holdings Inc. now owns 7,267 shares of the medical research company’s stock worth $456,000 after acquiring an additional 155 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Natera by 3.0% during the fourth quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock worth $389,000 after acquiring an additional 179 shares in the last quarter. Treasurer of the State of North Carolina raised its holdings in shares of Natera by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 45,469 shares of the medical research company’s stock worth $2,012,000 after acquiring an additional 230 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Natera by 0.3% during the third quarter. Royal Bank of Canada now owns 83,843 shares of the medical research company’s stock worth $3,710,000 after acquiring an additional 245 shares in the last quarter. Finally, Xponance Inc. raised its holdings in shares of Natera by 1.8% during the third quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock worth $642,000 after acquiring an additional 261 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

NTRA has been the subject of a number of recent analyst reports. Piper Sandler increased their price objective on Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Raymond James lowered Natera from a “strong-buy” rating to an “outperform” rating and increased their price target for the company from $68.00 to $85.00 in a research note on Tuesday, February 20th. BTIG Research increased their price target on Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, December 29th. Stephens reaffirmed an “overweight” rating and set a $78.00 price target on shares of Natera in a research note on Tuesday, January 30th. Finally, Craig Hallum initiated coverage on Natera in a research note on Monday, April 8th. They set a “buy” rating and a $117.00 price target for the company. One investment analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.